How Healthcare Investors Should Assess AI Exposure
Artificial intelligence is already reshaping workflows across healthcare, life sciences, and social care. But the implications for value creation are uneven-and many investors are pricing AI assets as if they've already won.
Two competing narratives dominate healthtech conferences. One promises that AI will transform everything from triage to drug discovery, making early investors winners in a once-in-a-lifetime opportunity. The other warns that most "AI software" assets are overpriced, and many won't survive when foundation-model providers, hyperscalers, or incumbent platforms ship comparable capabilities and turn differentiators into checkboxes.
The historical parallel is instructive. During gold rushes, the most durable fortunes went to those selling picks, shovels, and refining equipment-not mine owners. In the AI rush, value accrues to platforms, infrastructure, and workflow control points closest to distribution and switching costs: computer chips, cloud infrastructure, proprietary data, and systems-of-record. Everyone else risks feature parity and margin compression.
Healthcare is not e-commerce
Before applying any framework, one fact matters: healthcare remains accountable to regulation and liability in ways other industries don't. Even as AI models improve, human supervision will stay mandatory in most clinical use cases. "Human-in-the-loop" isn't a transitional phase-it's the operating model.
Radiology algorithms can triage worklists, but radiologists remain liable for findings. Ambient scribes can draft notes, but clinicians stay accountable for content. In surgery, the realistic picture isn't robots replacing surgeons; it's experienced clinicians supervising more activity through better tools, potentially across sites.
For investors, this shapes both adoption speed and value at stake. AI gains are real. But in healthcare, they usually arrive through gradual workflow redesign, governance, and change management-not overnight structural change.
The five-lens framework
A company can be highly exposed to AI without becoming obsolete. It can also have significant AI opportunity without facing urgent pressure to act today. Investors need to separate urgency to adapt from ability to capture upside.
Market diffusion speed: How quickly will AI change workflows and buyer expectations in this sector? In healthcare, diffusion depends less on what a model can do in a demo and more on deployment friction at scale. Public systems like the NHS typically lag in adoption due to weaker competitive incentives, long procurement cycles, and cultural resistance. Core healthcare IT vendors face higher urgency because AI embedded in their products becomes default-even if customer tech readiness constrains adoption. GxP-compliant contract manufacturers move slower; validation, regulation, and change control slow rollout regardless of demand.
Value at stake: Where does EBITDA actually come from? AI affects cognitive labour and repeatable information work most-documentation, interpretation, coding, planning, coordination. The harder question: can you monetize throughput gains, or will they be competed away? Teleradiology and pathology services have high value at stake because the core product is cognitive time. Clinical labs also face significant exposure, less from "AI reads the test" and more from standardizing operations, QC, and turnaround time at scale.
Competitive vulnerability: The threat isn't usually that AI replaces the service. It's that AI modularizes parts of it and shifts who controls the workflow. Staffing services face pressure not because clinicians disappear, but because AI compresses the coordination layer-matching, compliance, scheduling-pushing the market toward platform economics and lower agency margins.
Enduring advantage: In healthcare, defensibility is often non-software: referral capture, physical footprint, regulatory accreditation, deep integrations, and trusted track record. Contract manufacturers can be highly defensible; even if AI improves process development and batch release, scale and quality systems remain scarce. Hospitals benefit from local catchment, capital intensity, and regulation that dampen disruption. For them, AI is an efficiency race more than market reconfiguration.
Early adopter value capture: This is the crux. AI creates surplus, but surplus doesn't automatically accrue to the operator doing the work. It often gets competed away or passed through to customers. Medcomms agencies face rapid commoditization of drafting; defensible edges shift to compliance workflows, specialist expertise, and strategy. Device manufacturers can use AI to create a "device plus software plus data" bundle that defends pricing-if they execute on evidence, integration, and regulatory posture.
Sector-by-sector exposure
Core healthcare IT: Very high exposure and urgency. AI becomes a platform requirement. Value risks migrating to an AI workflow layer if incumbents don't ship fast.
Bioinformatics platforms: High urgency to adapt, but ability to win depends on workflow integration and access to proprietary data. Narrow point tools commoditize quickly.
Clinical labs and diagnostic support services: Moderate operational exposure with strong productivity upside, but value capture is constrained by buyer pressure unless contracts shift toward turnaround time, quality, reliability, or availability guarantees.
Contract manufacturers: Meaningful upside via right-first-time and faster release, but diffusion is slower and disruption is limited. AI is an operational edge, not an operating model shift.
Hospitals and social care: Lowest urgency. Near-term gains sit in documentation, coordination, and admin. Market structure and operating model impact will be limited.
How to diligence AI exposure
Map the value chain into tasks, not functions. Identify where cognitive labour, coordination, and documentation sit-and what's truly physical or relational.
Stress-test value capture. If productivity improves 20%, who keeps the 20%? Look at pricing units, contract terms, buyer concentration, and pass-through risk.
Run an execution readiness gate. Data rights, governance, integration capacity, cyber capability, and change management determine whether upside is realizable.
Translate into a 100-day plan. Pick two or three high-ROI use cases-often admin and workflow first-build governance, and decide whether to build, buy, or partner.
Where value actually settles
The most durable value accrues to businesses that own workflow control points, control scarce assets that remain scarce in an AI world, and can redesign their commercial model to capture surplus rather than pass it through.
The AI rush is real. But the winners will look less like "AI stickers on products" and more like disciplined operators and platforms that understand where the surplus goes-and get there first.
For healthcare professionals and investors, this means moving beyond use-case lists. The question isn't whether AI will change healthcare. It's where the value will settle-and whether your portfolio is positioned to capture it.
Your membership also unlocks:
